Metallothionein and anti-metallothionein, complementary elements of cadmium-induced renal disease.
Michael A Lynes,Xiuyun Yin
DOI: https://doi.org/10.1093/toxsci/kfj149
2006-01-01
Abstract:Metallothionein (MT) is a low–molecular weight, cysteinerich stress response protein with a high affinity for divalent heavy metals. MT was originally identified as a cadmium-rich protein in the equine renal cortex. A large amount of subsequent work has shown MT to serve in many cell types in the management of essential divalent metal cations, to interfere with the toxic effects of xenobiotics, heavy metals, and free radicals, and to serve as a regulator of specific transcription factors. As a consequence of these various activities, MT synthesis has an impact on developmental processes and on the cellular responses to stressful conditions (reviewed in (Klaassen et al., 1999; Vasak, 2005)). MT is primarily synthesized on free polysomes (Shapiro et al., 1980). Based on these observations, MT has often been considered to function exclusively as an intracellular protein. While MT lacks the signal peptide sequences or other protein trafficking signals that would result in the protein’s entering the traditional secretory pathway, it is nevertheless detected in serum, urine, pancreatic secretions, and other biological fluids as well as in bronchoalveolar spaces, liver sinusoids, and other extracellular spaces. This pool of extracellular MT may originate from necrotic cell death that may accompany some forms of stress, but it is also possible that MT may be selectively released from stressed cells by a nontraditional secretory pathway (Lynes et al., in press). Regardless of its origin, there is compelling evidence that this pool of extracellular MT has interesting roles of its own to play. One possible role of extracellular MT is as a distribution mechanism for both essential and toxic heavy metals. Another aspect of MT’s extracellular influences is its influence on immune capacity. Exogenous extracellular MT suppresses the adaptive immune response in vivo. This immunosuppression can be countered by the simultaneous injection of a monoclonal anti-MT antibody. The observation that injection of the monoclonal anti-MT antibody in the absence of exogenous MT can enhance the humoral immune response to T-dependent antigen challenge suggests that endogenous extracellular MT is capable of affecting immune regulation in a manner similar to that observed with exogenous sources of MT. This conclusion is supported by the observation that MT can be detected on the surface of splenic leukocytes from animals immunized in the presence of adjuvant and on the surface of leukocytes harvested from congenitally autoimmune animals. The nature of the binding of MT to these plasma membranes is as yet undefined: binding could be nonspecific via formation of mixed disulfides with cysteine-rich surface proteins such as CD45, it might be via interactions with pattern recognition receptors such as the Toll-like receptor family, or it might be a specific interaction with an MT-selective receptor as has been described on astrocytes (El Refaey et al., 1997). In light of the reports of anti-MT antibodies produced as a consequence of metal exposure, it may also be possible that MT interactions with some leukocyte plasma membranes are also mediated by Fc receptor capture of the immune complex on these cells. Injected exogenous MT can also suppress the progression of experimental autoimmune disease. Both experimental autoimmune encephalomyelitis (Penkowa and Hidalgo, 2003) and collagen-induced arthritis (Youn et al., 2002) are diminished in severity following treatment with exogenous MT. Conversely, targeted disruption of the Mt1 and Mt2 genes exacerbates the severity of viable moth-eaten congenital murine autoimmune disease (Lynes et al., 1999). From a biochemical standpoint, MT is a novel protein. Roughly 33 mol% (20 of 61 amino acids) of the MT sequence is cysteine. These cysteines play central roles in the capture of the divalent heavy metals that MT holds, and they also serve as targets for oxidant attack. The amino-terminal beta domain of the protein has been shown to contain the two immunodominant epitopes. Winge and Garvey (1983) showed that the principle antigenic determinants are to be found in residues 1–5 and 25– 30 within MT’s beta domain. In contrast, the COOH-terminal 1 To whom correspondence should be addressed at Department of Molecular and Cell Biology, 91 N. Eagleville Road, University of Connecticut, Storrs, CT 06269-3125. E-mail: michael.lynes@uconn.edu.